Article PDF first page preview

First page of Natural History of Cow’s Milk Protein Allergy in Preterm Infants: Insights from a Retrospective Cohort Study

Background and objectives: Cow’s-milk protein allergy (CMPA) affects approximately 2-3% of healthy children. The natural history of CMPAis poorly described in preterm infants. The aim of the study is to determine disease characteristics and long-term natural history of CMPAin preterm infants. Methods: This was a retrospective cohort study of Clalit Health Services (CHS) members (the largest of 4 integrated health care organizations in Israel). The medical records of children, who developed, as preterm infants, symptoms suggestive for CMPA during their hospitalization at the neonatal intensive care unit between June 2009 and June 2020 and subsequently were attending primary care clinics of the CHS in Northeastern Israel, were retrospectively reviewed for clinical manifestation and laboratory variables at disease onset and during follow-up. Results: Among 141 preterm infants (mean gestational age 31 weeks, median follow-up 3.4 years), CMPA persistence was 16% at 1 year, 1.8% at 3 years, and 1.5% at 6 years. Atopic conditions developed at 39%, with asthma being most frequent (31%). Cesarean delivery was associated with higher risk of subsequent atopic disease (HR 1.22, p=0.009). Conclusions: CMPA in preterm infants often resolves by one year. Accurate diagnosis and earlier reintroduction of cow milk protein may improve outcomes and reduce unnecessary interventions.

Journal Section:
Clinical Allergy
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.